China has approved what is being described as the world’s first brain-computer chip for commercial use, marking a major step in neurotechnology and putting it ahead of Elon Musk’s Neuralink in bringing such implants to market.

The coin-sized implant, known as NEO, has reportedly completed clinical trials and is designed initially to help patients with spinal cord injuries and paralysis by enhancing nervous system function.

It is expected to enter mass production for use within China’s state-run healthcare system, with early deployment focused on medical rehabilitation applications.

The development has sparked renewed global attention on brain-computer interface technology, an emerging field also being pursued by Neuralink, the neurotechnology company founded by Elon Musk.

Musk has previously described the potential of such implants as transformative, including restoring movement and vision in patients with severe neurological conditions.

Neuralink has also been testing devices that aim to allow users to control digital interfaces through thought.

Experts say the technology could eventually extend beyond medical use into broader human-machine integration, though they caution that it raises major ethical and security concerns.

Cybersecurity specialists have warned that brain implants could expose highly sensitive neural data, including thoughts and memories, to hacking risks or misuse by corporations or hostile actors.

Analysts also say issues of data ownership and privacy will become central as the technology develops, given the intimate nature of brain activity compared with existing digital tracking systems.

While proponents argue brain-computer chips could benefit billions of people with neurological disorders such as Parkinson’s disease, epilepsy and stroke, researchers note that the technology remains experimental and carries medical risks.

These include potential brain damage, immune rejection, infection, and complications from implanting devices in sensitive neural regions.

The Chinese-developed implant is currently reported to be entering early large-scale production, while Neuralink’s system is still undergoing limited human trials and awaiting broader regulatory approval.